Trial Profile
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Parallel-Group, Phase 3 Study to Assess the Efficacy and Safety of Ketotransdel in the Treatment of Pain Associated with Mild to Moderate Acute Soft Tissue Injury
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 06 Dec 2023
Price :
$35
*
At a glance
- Drugs Ketoprofen (Primary)
- Indications Acute pain; Musculoskeletal pain
- Focus Registrational; Therapeutic Use
- Sponsors Harrow; Harrow Health; Imprimis Pharmaceuticals
- 02 Sep 2010 Primary endpoint results presented at the 13th World Congress on Pain
- 02 Sep 2010 Results from the final data were presented at the 13th World Congress on Pain in Montreal, Canada, according to a Transdel Pharmaceuticals media release.
- 25 May 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.